Primary plasma cell leukemia (pPCL) is an aggressive plasma cell disorder with a guarded
prognosis. The diagnosis is confirmed when peripheral blood plasma cells (PCs) exceed …

Multiple myeloma (MM) is a genetically complex disease. The key myeloma-initiating
genetic events are hyperdiploidy and translocations involving the immunoglobulin heavy …

PURPOSE Primary plasma cell leukemia (PCL) is the most aggressive monoclonal
gammopathy. It was formerly characterized by≥ 20% circulating plasma cells (CTCs) until …

PURPOSE Primary plasma cell leukemia (pPCL) is an aggressive subtype of multiple
myeloma, which is distinguished from newly diagnosed multiple myeloma (NDMM) on the …

The outcomes of patients with primary plasma cell leukemia (pPCL) after undergoing
hematopoietic cell transplantation (HCT) in the novel agent era are unknown. We report …

The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging
despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti‐apoptotic …

Multiple myeloma remains an incurable disease despite numerous novel agents being
approved in the last decade. Furthermore, disease behavior and susceptibility to current …

Despite the introduction of novel agents, multiple myeloma remains incurable for most
patients, necessitating further therapeutic options. Venetoclax, a selective BCL-2 inhibitor …

Abstract Venetoclax (ABT-199), a BH3-mimetic and selective BCL-2 inhibitor, was recently
approved by the US Food and Drug Administration (FDA) for the treatment of acute myeloid …

Background Primary plasma cell leukaemia is a rare and aggressive plasma cell disorder
with a poor prognosis. The aim of the EMN12/HOVON-129 study was to improve the …